Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Regulus Therapeutics nets $48.3mm through initial public offering

Executive Summary

Less than two months after filing its S-1, Regulus Therapeutics Inc. (single-stranded oligonucleotide therapeutics) has netted $48.3mm in its initial public offering of 12.9mm shares (including the overallotment) for $4. Last month, the company anticipated selling 4.6mm shares at $10-12.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies